|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 62.46 CNY | +1.36% |
|
+0.84% | +36.08% |
| 12-08 | Hengrui Medicine's 20 Drugs Included in China's Reimbursement Drug List | MT |
| 12-08 | Jiangsu Hengrui Medicine Gets Inclusion in China's Medical Insurance Catalog | MT |
| Capitalization | 415B 58.65B 50.48B 47.39B 44.05B 81.2B 5,287B 88.59B 552B 214B 2,496B 220B 215B 9,146B | P/E ratio 2025 * |
47.1x | P/E ratio 2026 * | 42.9x |
|---|---|---|---|---|---|
| Enterprise value | 376B 53.16B 45.76B 42.96B 39.93B 73.6B 4,792B 80.3B 501B 194B 2,263B 200B 195B 8,290B | EV / Sales 2025 * |
11.4x | EV / Sales 2026 * | 10x |
| Free-Float |
52.38% | Yield 2025 * |
0.44% | Yield 2026 * | 0.51% |
| 1 day | +1.36% | ||
| 1 week | +0.84% | ||
| Current month | +0.61% | ||
| 1 month | +1.43% | ||
| 3 months | -13.62% | ||
| 6 months | +16.10% | ||
| Current year | +36.08% |
| 1 week | 60.7 |  | 63.55 |
| 1 month | 59.31 | | 63.9 |
| Current year | 42.4 | | 74.04 |
| 1 year | 42.4 | | 74.04 |
| 3 years | 35.51 | | 74.04 |
| 5 years | 27 | | 97.39 |
| 10 years | 12.9 | | 97.39 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jian Jun Liu
DFI | Director of Finance/CFO | 48 | 18/11/2021 |
Ji Feng
PSD | President | - | 01/04/2025 |
Yu Xu
CMP | Compliance Officer | 33 | 31/05/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Jie Ping Sun
BRD | Director/Board Member | 55 | 15/01/2020 |
Hong Bin Dai
BRD | Director/Board Member | 49 | 15/01/2020 |
Piao Yang Sun
CHM | Chairman | 66 | 07/07/2021 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 4.18% | 0 M€ | -19.71% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.36% | +0.84% | +26.11% | +60.69% | 57.93B | |
| -1.26% | -5.70% | +20.67% | +168.32% | 905B | |
| -0.15% | -1.81% | +35.03% | +13.78% | 487B | |
| -1.31% | -0.88% | +26.64% | +34.42% | 400B | |
| +2.19% | +2.82% | +23.62% | +4.87% | 330B | |
| -0.10% | -1.86% | +27.45% | +19.99% | 281B | |
| -0.41% | +2.28% | +18.74% | +25.02% | 255B | |
| -0.79% | -2.85% | -4.04% | -10.75% | 248B | |
| -3.42% | -4.91% | -61.94% | -33.36% | 214B | |
| -2.63% | -4.82% | +17.85% | +12.49% | 178B | |
| Average | -0.67% | -1.44% | +13.01% | +29.55% | 335.44B | |
| Weighted average by Cap. | -0.76% | -2.34% | +17.02% | +54.33% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 33.04B 4.67B 4.02B 3.78B 3.51B 6.47B 421B 7.06B 44.01B 17.04B 199B 17.54B 17.16B 729B | 36.88B 5.22B 4.49B 4.21B 3.92B 7.22B 470B 7.88B 49.12B 19.02B 222B 19.58B 19.16B 813B |
| Net income | 8.76B 1.24B 1.07B 1B 930M 1.71B 112B 1.87B 11.66B 4.52B 52.72B 4.65B 4.55B 193B | 9.65B 1.37B 1.18B 1.1B 1.03B 1.89B 123B 2.06B 12.86B 4.98B 58.11B 5.12B 5.01B 213B |
| Net Debt | -38.82B -5.49B -4.73B -4.44B -4.12B -7.6B -495B -8.29B -51.7B -20.02B -234B -20.6B -20.16B -856B | -45.64B -6.46B -5.56B -5.22B -4.85B -8.94B -582B -9.75B -60.79B -23.54B -275B -24.23B -23.71B -1,007B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/12/25 | 62.46 ¥ | +1.36% | 50,861,750 |
| 05/12/25 | 61.62 ¥ | +0.60% | 23,117,610 |
| 04/12/25 | 61.25 ¥ | +0.46% | 18,040,760 |
| 03/12/25 | 60.97 ¥ | -0.25% | 19,852,970 |
| 02/12/25 | 61.12 ¥ | -1.32% | 18,230,610 |
End-of-day quote Shanghai S.E., December 07, 2025
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 600276 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition